Microvascular alterations in hypertension and vascular aging by Savoia, Carmine et al.
Send Orders for Reprints to reprints@benthamscience.ae 
 Current Hypertension Reviews, 2017, 13, 000-000 1 
RESEARCH ARTICLE 
  1573-4021/17 $58.00+.00 © 2017 Bentham Science Publishers 
Microvascular Alterations in Hypertension and Vascular Aging 
Carmine Savoia1,*, Alleggra Battistoni1, Valentin Calvez1, Vincezo Cesario1, Giulio Montefusco1 
and Antonio Filippini2 
1Clinical and Molecular Medicine Department, Cardiology Unit, Faculty of Medicine and Psychology, Sant’Andrea 
Hospital, Sapienza University of Rome, Rome, Italy; 2Department of Anatomical Sciences, Histological, Legal Medical 
and Locomotor, Sapienza University of Rome, Rome, Italy 
Abstract: Hypertension and aging are characterized by vascular remodelling and stiffness as well 
as endothelial dysfunction. Endothelial function declines with age, since aging is associated with 
senescence of the endothelium due to increased rate of apoptosis and reduced regenerative capacity 
of the endothelium. Different phenotypes of hypertension have been described in younger and adult 
subjects with hypertension. In younger patients, functional and structural alterations of resistance 
arteries occur as the earliest vascular alterations which have prognostic significance and may con-
tribute to stiffness of large arteries through wave reflection. In individuals above age of 50 years as 
well as in subjects with long-lasting elevated blood pressure, vascular changes occur predominantly 
in conduit arteries which become stiffer. Activation of renin-angiotensin-aldosterone and endothelin 
systems plays a key role in endothelial dysfunction, vascular remodelling, and aging by inducing 
reactive oxygen species production, and promoting inflammation and cell growth. 
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INTRODUCTION 
 Hypertension and cardiovascular disease increase with 
advancing age as shown in epidemiological studies. In  
particular, hypertension is an important risk factor for vascu-
lar senescence [1], resulting in premature cardiovascular 
disease. 
 In younger patients, increased peripheral vascular  
resistance is a common feature of essential hypertension. In 
presence of elevated blood pressure, vascular remodelling 
may occur over time particularly in the wall of large arteries 
through sustained stretch on the vascular wall which  
activates distinctive intracellular pathways [2], resulting in 
structural and functional alterations that eventually induce 
vascular stiffness, increased systolic blood pressure and may 
contribute to the progression of atherosclerosis [3]. 
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 In this regard, hypertensive vascular alterations and the 
age-associated changes in blood vessels share similar pheno-
types, including structural changes (increased arterial wall 
thickness and stiffness as well as reduced compliance and 
lumen diameter) [1, 4], vascular inflammation [5, 6], and 
impaired endothelial function due to increased oxidative 
stress and decreased production of vasodilator agents such as 
nitric oxide (NO) [7]. 
 Alterations in vascular tone at level of resistance arteries 
play an important role in the pathophysiology of hyperten-
sion by increasing peripheral resistance which is the most 
important site of pulse wave reflection that contributes to the 
stiffness of large arteries [3]. Impaired endothelial function 
is a common feature of hypertension and largely participates 
in the increased constriction of resistance arteries [8]. Also 
aging contributes to endothelial dysfunction which is charac-
terized by reduced vasodilation and increased endothelium-
dependent contraction, vascular permeability and a pro-
inflammatory and prothrombotic phenotype. The latter is 
characterized by leucocyte-endothelial interactions that par-
ticipate in vascular inflammation and increased adhesion and 
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pendently associated with increased cardiovascular risk [12]. 
The activation of inflammatory process in vascular and peri-
vascular tissue is recognized as an important determinant in 
the pathophysiology of the structural alterations in the vascu-
lar wall of resistance and large arteries [13]. This may con-
tribute to the development of the increased vascular resis-
tance and vascular stiffness in large arteries as well as to the 
development of atherosclerosis [14, 15]. Vascular stiffness 
can be evaluated by carotid-femoral pulse wave velocity 
(PWV), that is associated with target organ damage and in-
creased risk for cardiovascular morbidity and mortality [16]. 
 It is well assessed that renin-angiotensin system (RAS) 
plays a key role in the pathophysiology of hypertension [17], 
contributing to oxidative stress, vascular inflammation, and 
thus to endothelial dysfunction. 
 This review will focus on the alterations that occur in the 
vascular wall particularly in resistance arteries (lumen di-
ameter of 100-300 µm) in hypertension and vascular aging. 
ENDOTHELIAL DYSFUNCTION 
 The endothelium may be considered the largest organ in 
the body as it is able to generate several factors that regulate 
vascular tone, vascular permeability, angiogenesis, and the 
response to inflammation. NO is the main modulator of en-
dothelial function since it induces vasodilation, and exerts 
antioxidant and antinflammatory function [18], by inhibiting 
leukocyte adhesion [19], thrombocyte aggregation [20] and 
smooth muscle cell proliferation [21] . 
 Endothelial dysfunction is characterized by the impair-
ment of endothelium-induced vasodilation, enhanced vaso-
constriction and increased production of reactive oxygen 
species (ROS), thus it may contribute to the inflammation of 
the vascular wall [9, 11, 16, 17, 22, 23] and therefore to the 
remodelling of the arterial wall that typically occurs in hy-
pertension as well in aging. 
 Endothelial dysfunction is one of the most important age-
associated cardiovascular changes [24, 25], that may occur in 
association with other important cardiovascular risk factors 
such as hypertension, diabetes dyslipidemia, and obesity. 
 Endothelium-dependent vasodilatation progressively de-
clines with age as assessed by several clinical and experi-
mental studies in different vascular beds including resistance 
arteries [25-29]. This may contribute to the development of 
hypertension as well to the hypertension related vascular 
alterations. Several putative mechanisms have been advo-
cated to explain this effect including the breakdown of NO 
and other endothelial-derived substances such as prostacy-
clin and the endothelium-derived hyperpolarizing factor 
(EDHF) [30], independently of the structural changes in the 
vascular wall [31-38]. This, in turn, is associated with an 
enhanced reactivity to vasoconstrictors [39]. It has been re-
ported that endothelial NO synthase (eNOS) expression and 
NO production decline with age [35, 40-42]. This may occur 
through the reduced eNOS mRNA expression and stability 
[43] due to the age-related decrease in shear stress [44] as 
well as by the age-related reduction of growth factors includ-
ing human growth hormone (GH) [45]. Interestingly, physi-
cal training as well as therapy with GH improves eNOS ex-
pression and endothelial function in aged rats [42, 46] and 
humans [47-49]. 
 Aging is associated with increased ROS production par-
ticularly in endothelial cells. Indeed, removal of the endothe-
lium and the inhibition of the nicotinamide adenine dinucleo-
tide phosphate (NADPH) oxidase (the main source of ROS 
in the vasculature) reduce vascular superoxide generation in 
the aorta of aged rats [50-55]. 
 The increased production of ROS in the vasculature con-
tributes to the reduced NO bioavailability and to the im-
paired relaxation [35, 38, 50] particularly in the microcircu-
lation [39]. This may occur through the uncoupling of the 
eNOS [35] and the generation of peroxynitrite [35, 56], 
which is a highly reactive oxidizing agent [57]. In fact, per-
oxynitrite is able to penetrate across cellular membranes and 
by substrate nitration, it may inactivate different enzymes, 
including free radical scavengers [35, 58]. Thus, the in-
creased formation of peroxynitrite and reduced NO bioavail-
ability during aging may inactivate antioxidative enzymes 
including superoxide dismutase (SOD) [56, 59]. Therefore, 
also cellular antioxidative defense systems are attenuated 
with aging [60]. This can further contribute to the enhanced 
production of ROS and endothelial dysfunction. Further-
more, it has been shown that the expression of inducible NO 
synthase (iNOS) is enhanced within the vascular wall of 
aged rats [35, 61]. iNOS further promotes oxidative stress 
through the enhanced generation of superoxide anion and the 
formation of peroxynitrite [57, 62]. ROS is also produced by 
mitochondria [63-69] and contributes to mitochondrial dys-
function which is progressively increased in vascular aging. 
In particular, it has been shown that mice lacking the mito-
chondrial p66Shc adaptor protein presented reduced produc-
tion of intracellular ROS, increased NO bioavailability and 
improved endothelial dysfunction [70]. These features are 
associated with no age-dependent changes in iNOS as well 
as with prolonged life span [71]. Thus, the modulation of 
p66Shc function could be relevant for the protection from 
age-dependent endothelial dysfunction. 
 Vascular senescence is also associated with reduced ca-
pacity of the endothelium to regenerate [72-74]. Under nor-
mal conditions, endothelial cells present a low turnover rate 
[75], with aging endothelial cells expressing negative cell 
cycle regulators (i.e. p53 and p16) [76-79], and are charac-
terized by impaired secretion of and/or sensitivity to growth 
factors which lead to growth arrest and senescence. Moreo-
ver, aged endothelial cells show also suppressed activity of 
telomerase reverse transcriptase [80-82], which is associated 
with shorter telomere length that is inversely related to 
chronological age in endothelial cells [80, 81]. Interestingly, 
RAS activation and increased ROS production contribute to 
the reduction of the telomerase activity as well as to DNA 
damage and genomic instability. These are all-important 
promoters of cellular senescence [83-88] in the vasculature. 
 Also angiogenesis reduces with aging; in particular, en-
dothelial senescence may be responsible for some processes 
that are typically observed in the elderly such as the impaired 
wound healing and angiogenesis [89]. In experimental model 
of senescence both in mice and humans, an imbalance be-
tween pro-angiogenic and anti-angiogenic factors has been 
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described, particularly in microvascular endothelial cells. 
Specifically, the pro-angiogenic factors such as tissue inhibi-
tor of metalloproteinase-2 (TIMP-2) [90] and the throm-
bospondin-2 [91] are increased, whereas, the anti-angiogenic 
factors such as vascular endothelial growth factor (VEGF) 
and transforming growth factor-β 1 (TGF-β1) are reduced. 
These alterations are associated with reduced matrix deposi-
tion and reduced angiogenesis-associated inflammation 
which are required for angiogenesis. Moreover, also circulat-
ing endothelial progenitor cells (EPCs) are an important de-
terminant for the potential capacity of endothelium regenera-
tion as well as of endothelial function. EPCs are significantly 
reduced in aging [92] as well as in hypertensive conditions 
[93, 94]. Finally, decreased EPCs numbers are also associ-
ated with decreased endothelial function [94] and arterial 
stiffness [95]. 
REMODELLING OF RESISTANCE ARTERIES 
 Vascular remodelling is typically found in resistance ar-
teries of hypertensive individuals and is characterized by 
reduced vascular lumen with increased media thickness (i.e. 
increased media-to- lumen ratio - M/L-). These alterations 
may be functional, mechanical and/ or structural [3, 96]. It 
has been well documented that M/L is considered the most 
reproducible parameter of vascular remodelling of resistance 
arteries [3, 97]. A smaller lumen and the increased media 
thickness decrease circumferential tension and reduce media 
stress in order to protect the wall of the artery from the ef-
fects of elevated blood pressure. On the other hand, small 
decreases in the lumen diameter significantly increase resis-
tance to blood flow, which can contribute to maintaining 
elevated blood pressure values. Interestingly, increased M/L 
ratio is associated with the occurrence of cardiovascular 
events [98]. It is thought that increased M/L ratio could be 
the earliest alteration that occurs in the vasculature [99], and 
may precede endothelial dysfunction in hypertensive pa-
tients. Among the factors that may contribute to the struc-
tural alterations of the arterial wall, the variation of myo-
genic tone (i.e. the intrinsic ability of vessels to constrict in 
response to increased intraluminal pressure) may exert a sig-
nificant contribution [100]. Moreover, increased concentra-
tion of specific agonists including Ang II and endothelin 
may also contribute to vasoconstriction and vascular remod-
elling by increasing the intracellular calcium levels, protein 
kinases, diacylglycerol, ROS generation [100, 101], and ex-
tracellular matrix deposition. These alterations may occur in 
hypertension as well as in aging. With chronic vasoconstric-
tion, vessels may become embedded in a remodelled ex-
tracellular matrix and may not return to their dilated state [3, 
100], and in turn, structural narrowing of the lumen may 
amplify vasoconstriction. Two different types of vascular 
remodelling have been described: eutrophic and hypertrophic 
vascular remodelling. Hypertrophic remodelling is character-
ized by the increased M/L together with increased media 
cross-sectional area, whereas in eutrophic remodelling, the 
media cross-section does not increase [3, 97], rather smooth 
muscle cells are reorganized around a smaller lumen which 
leads to increased M/L. Although both eutrophic and hyper-
trophic remodelling may occur in the same subject in differ-
ent vascular beds, these types of vascular remodelling occur 
in distinct types of arterial hypertension. Eutrophic vascular 
remodelling is generally found in mild-to-moderate hyper-
tension and is also combined with enhanced apoptosis in the 
periphery of the vessel [101, 102]. In experimental animals, 
eutrophic remodelling is often associated with activation of 
the RAS. If hypertension is severe or longstanding as well as 
whether the myogenic reflex and the autoregulatory mecha-
nisms are dysfunctional, the increase in the wall stress may 
induce hypertrophy. Hypertrophic remodelling of resistance 
arteries is more prevalent in renovascular hypertension 
[103], diabetic subjects [104, 105] and acromegalic patients 
[106], and may also occur in hyperaldosteronism. 
Mechanism of Vascular Remodelling 
 The molecular mechanisms involved in the remodelling 
of resistance arteries are not fully understood and are in part 
similar to those involved in vasculature aging. Several fac-
tors may be involved in this process including the activation 
of RAS, the enhancement of inflammation, growth and pro-
fibrotic processes, as well as the modification of VSMCs and 
extracellular matrix components [107]. The reorganization of 
the vessel wall components (including collagen, elastin, and 
other components of extracellular matrix) around a narrower 
lumen occurs in eutrophic remodelling of resistance arteries, 
whereas cell growth and deposition of extracellular matrix 
components contribute to media thickening in hypertrophic 
remodelling [108-110]. Cell growth and extracellular matrix 
deposition may result from blood pressure elevation and /or 
from growth- promoting factors including Ang II, endo-
thelin-1, and cathecolamines. Several experimental data have 
shown that also the reduced activity of matrix metalloprote-
inases (MMPs) may play a role in the remodelling of the 
extracellular matrix in the vascular wall. MMP-1 is reduced 
in the serum of hypertensive patients with increased vascular 
level of type I collagen [111] as well as MMP-2 and MMP-3 
activity are reduced in spontaneously hypertensive rats 
[112]. Furthermore, the decrease of MMPs activity in resis-
tance arteries is associated with accumulation of collagen 
type IV and V and fibronectin [113]. Moreover, in rat mes-
enteric arteries, MMP-2 is associated with the reduction of 
the vasoconstrictor effects of the precursor of endothelin-1, 
the big endothelin-1 [114]. This may contribute to endothe-
lial dysfunction, vasospasm, blood pressure elevation and its 
related cardiovascular complications. [115]. Moreover, in 
vascular aging, particularly in large arteries, polymorphisms 
of MMP-3 and MMP-9 have been associated with vascular 
remodelling and arterial stiffness [116, 117]. VSMCs are 
multifunctional cells, which significantly contribute to vas-
cular function and tone. Alteration of VSMCs is associated 
to arterial remodelling in aging and hypertension through 
different mechanisms, including hyperplasia, cell growth, 
apoptosis, cell elongation and reorganization as well as to 
new production of extracellular matrix proteins, inflamma-
tion of the arterial wall, and fibrosis [118-121]. Detachment 
of VSMCs and endothelial cells, decreased endothelial pro-
genitor cells, and increased microparticles may further con-
tribute to vascular dysfunction and remodelling [111, 122, 
123]. Apoptosis is an important mechanism that may con-
tribute to structural remodelling of the arterial wall in aging 
and hypertension [111, 123], although its role is not fully 
understood. In particular, apoptosis could be either a primary 
event that may occur in the vasculature in hypertensive con-
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ditions and aging or may be part of a growth-associated 
compensatory process. Thus an imbalance between growth 
and apoptosis could be relevant in vascular remodelling. 
 RAS activation plays a key role in the pathophysiology 
of vascular remodelling [2]. Ang II may induce vascular re-
modelling by several mechanisms including vasoconstric-
tion, cell growth, oxidative stress and inflammation. Mainly 
in hypertensive conditions, Ang II and aldosterone, as well 
as endothelin-1 enhance the basal superoxide production by 
the activation of NADPH oxidase and expression of its 
subunits via the activation of cSrc, PKC (protein kinase C), 
PLA2 (phospholipase A2) and PLD (phospholipase D) 
pathways [8, 124-126]. Increased ROS production contrib-
utes to the development of vascular dysfunction and arterial 
remodelling in part by impairing endothelium-derived NO 
bioavailability as well as by inducing VSMCs proliferation 
and hypertrophy, collagen deposition in the vascular wall 
and by inducing the release of pro-inflammatory cytokine 
and transcription factors (i.e. NF-κB). These processes may 
lead to the functional and structural changes in the circula-
tion, and may participate in the development and progression 
of atherosclerosis in large arteries. 
 RAS activity is potentiated by the activation of mineralo-
corticoid receptors that may contribute to inflammation, fi-
brosis and vascular dysfunction and damage. In this regard, 
aldosterone enhances the activity of tissue angiotensin-
converting enzyme [125] and up-regulates angiotensin recep-
tors [126] as well as aldosterone induces ROS formation and 
endothelial dysfunction in several organs including heart and 
brain, as described in different experimental settings in ani-
mal models of cardiovascular disease [126]. Thus, mineralo-
corticoid antagonism may attenuate these deleterious effects 
by reducing directly the pro- inflammatory and pro-fibrotic 
effects of aldosterone [127, 128]. 
 Importantly, inflammation of the vascular wall partici-
pates in vascular remodelling by promoting the cell growth 
and VSMCs proliferation, thus contributing to the acceler-
ated vascular damage in aging and in hypertensive condi-
tions [13], as well as to the initiation and progression of athe-
rosclerosis and the development of cardiovascular and cere-
brovascular diseases [14, 15, 129, 130]. In the context of 
inflammation, an important role is played by adhesion mole-
cules (VCAM-1, ICAM-1) which are increased on the endo-
thelial cell membrane at the early stage of the inflammatory 
process. This leads to the accumulation of monocyte/ 
macrophages, and lymphocytes [131] in the arterial wall. 
 Also perivascular fat is involved in vascular remodelling 
since it exhibits inflammatory changes characterized by in-
creased generation of inflammatory mediators such as Tu-
mor Necrosis Factor (TNF)-alpha and increased production 
of oxidative stress, as well as reduced adiponectin produc-
tion that may contribute to a contractile phenotype [132, 
133]. 
 A large body of evidence indicates that innate immunity 
may be involved in the mechanisms that contribute to the 
vascular inflammation, particularly in hypertension. Experi-
mental data showed that the reduction of Treg and the im-
pairment T effector upregulation are associated with in-
creased blood pressure and are involved in the pathogenesis 
of blood pressure-induced vascular inflammation and car-
diovascular remodelling. In this regard, an imbalance be-
tween pro-inflammatory subsets of T lymphocytes (Th1, Th2 
and Th17) and the anti-inflammatory T regulatory (Treg) 
cells might be in part responsible for the inflammatory re-
sponse in cardiac and metabolic diseases [134]. It has been 
shown that Ang II and increased ROS production are impor-
tant modulators of T-cell activation [135-139] as well as 
Treg cells adoptive transfer may exert a blood pressure low-
ering effect and modulation of vascular remodelling in mice 
infused with either AngII [136] or aldosterone [137]. Fur-
thermore, mice deficient in vascular macrophages and in T- 
and B- lymphocytes did not present vascular remodelling in 
response to Ang II- or DOCA-salt [13, 135]. 
 Rarefaction is a different type of remodelling process 
which occurs in hypertension and aging at the level of 
smaller arterioles (lumen diameter <40 u) [3]. With this 
process, the density of arterioles per unit of tissue is reduced, 
thus vascular resistance is increased [140]. In particular, in 
hypertension, vasoconstriction may induce a functional re-
duction of small arterioles that may become anatomically 
permanent, resulting in decreased tissue perfusion. 
CONTRIBUTION OF THE INCREASED PERIPHERAL 
RESISTANCE TO THE REMODELLING OF CONDUIT 
ARTERIES 
 Aging and elevated blood pressure are the two major 
determinants of increased arterial stiffness in conduit arteries 
[41]. In patients with long lasting hypertension, or in adult 
subjects (age >50 years), large conduit arteries such as aorta 
become stiffer because of age-related processes which sig-
nificantly contribute to systolic blood pressure increase. In-
terestingly with aging, diastolic blood pressure tends to de-
crease, leading to increased pulse pressure (PP). In younger 
individuals, who have a more elastic arterial wall in conduit 
arteries, PP increases from central to peripheral arteries. This 
is due to the summation of the incident and the reflected 
waves more distantly along compliant arteries. Reflected 
waves originate at different vascular sites from the peripheral 
vasculature, mainly in resistance sites. In an elastic and 
compliant vasculature, reflected waves return towards the 
heart in diastole [141]. With aging, reflected waves return at 
faster velocity in stiffer arteries, as well as the forward 
waves from the heart toward the periphery are accelerated, 
thus the net result is the earlier summation of both forward 
and reflected waves in the cardiac cycle, leading to the am-
plification and increase of the aortic systolic pressure. This 
augmentation contributes to the absence of amplification 
toward the periphery, which is associated to the increased 
aortic and peripheral systolic blood pressure and PP. Moreo-
ver, it contributes further to the increased stiffness of central 
elastic arteries. Hypertension may accelerate these mecha-
nisms. Resistance arteries may play a determinant role in this 
process as the remodelled resistance arteries are not only the 
site of vascular resistance but possibly the origin of large 
part of wave reflection in aorta [142]. In turn, increased stiff-
ens and pulsatility in aorta are transmitted to resistance arter-
ies and may contribute to vascular injury in this vascular 
district [143]. The velocity of propagation of the pressure 
Microvasculature in Aging Current Hypertension Reviews, 2017, Vol. 13, No. 0    5 
wave along the conduit arteries may be measured through the 
PVW by tonometric evaluation [142]. Aortic PWV increases 
with advancing age and is probably the most accurate meas-
ure available of aortic stiffness. [144]. 
 A possible association between indices of conduit arterial 
stiffness and M/L ratio of resistance arteries has been de-
scribed [145]. M/L ratio was significantly related to brachial 
systolic blood pressure and PP and to central systolic blood 
pressure and PP. Moreover, a positive correlation was ob-
served between M/L ratio and carotid femoral PWV inde-
pendently of age and mean blood pressure [145]. A link be-
tween extracellular matrix molecules and aortic stiffness has 
also been described. Aortic stiffness is correlated with the 
expression of genes involved in increased vascular tone and 
remodelling and in long term sustained contraction (i.e. pro-
tein phosphatase-1, the catalytic subunit of myosin light 
chain phosphatase, members of the family of A kinase an-
chor protein) [146, 147] as well as with deposition of colla-
gen, fibronectin and non-fibrillar extracellular material in the 
media. The increase in aortic stiffness and reduced compli-
ance of conduit arteries may contribute to the increase in 
central pressure and to the development of isolated systolic 
hypertension (ISH) that represents the most common type of 
hypertension in the elderly [16]. 
CONCLUSION 
 Hypertension and aging share similar mechanisms of 
vascular dysfunction. Vascular remodelling, endothelial dys-
function and vascular stiffness are common features in hy-
pertension and aging. Several agonists may contribute to 
these alterations observed in the vasculature in hypertension 
and aging. The activation of RAS plays a central role in the 
genesis of endothelial dysfunction and vascular remodelling 
by activating redox-sensitive pathways and promoting cell 
growth and inflammation. Functional and structural altera-
tions of resistance arteries may represent the earliest vascular 
alterations in hypertensive patients which can contribute to 
maintain the increased blood pressure values over time, since 
small arteries and arterioles are the site of vascular resistance 
to blood flow. Moreover, resistance arteries are also consid-
ered the origin of most of the wave reflections contributing 
to the stiffness of large arteries and the increased central sys-
tolic blood pressure in the elderly. Thus, the alterations in the 
microvasculature may contribute and/or accelerate the aging 
of conduit arteries. Nevertheless, the relationship between 
the stiffness of conduit and microvascular dysfunction may 
be bidirectional, since the transmission of increased arterial 
pulsatility to resistance arteries could represent also a 
mechanism of damage at this level. 
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